Dr. Norbert Windhab

 Dr. Norbert Windhab is heading the function Strategic Projects at Evonik Industries AG Business Line Health Care since 2008. He spun out the JV from Aventis SA with Nanogen Inc., CA, in the field of DNA-based diagnostics and drug-research as its Managing Director in 2001 and entered Degussa AG, now Evonik Industries in 2005 to initiate clinical programs in nutraceutical product innovation and novel functional drug delivery excipients.

Dr. Windhab is scientific board member at the University of Freiburg BIOSS Government Excellence Center and in the Kuratorium of the Max Planck Institute in Cologne. He is lecturer Pharma Polymers at the University of Jena and invited auditor to Fraunhofer Institutes.

He was R&D head “Bioorganic Systems” at Aventis R&T from 1998 until 2001. In 1996 he became project director chip-diagnostics at Hoechst AG’s R&T central research. In 1994 he joined Albert Eschenmoser’s laboratories (ETH-Zürich/ Scripps Institute, La Jolla CA) for post-doctoral research. He obtained his PhD in Biophysical Chemistry at the Freiburg University in 1993 on the synthesis and bio-physical properties of bio-polymers and RNA model compounds. He was member of the scientific advisory board of the venture fund Polytechnos II in Munich until 2005.

He published scientific and strategic articles and holds numerous patents in peptide actives chemistry, drug R&D and delivery technology in the fields of life-sciences, supra-molecular chemistry and biopolymers.